News | Cardiac Imaging | March 24, 2017

Philips Showcases Data-Driven Cardiology Solutions at ACC.17

Next-generation Live 3-D TEE, highly anticipated iFR trial outcomes highlight company’s cardiovascular offerings

Philips, cardiology solutions, ACC.17, Azurion angiography system, iFR outcomes results, IntelliSpace Cardiovascular

March 24, 2017 — At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad range of integrated, patient-centric solutions designed to address the prevention, diagnosis, minimally invasive treatment and chronic care at home of cardiac conditions.

Philips exhibited the company's advanced, connected health offerings in the cardiology space at ACC.17, including:

  • Azurion – The company’s recently launched, next-generation image-guided therapy platform allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care. Azurion is powered by ConnectOS, a new operating system that provides a seamless integration of real-time information from all relevant technologies in the interventional lab.
  • Evolution 3.0 – Philips introduced the X8-2t Live 3D TEE (transesophageal echo) transducer, which allows for new levels of live 3-D imaging with new 3-D TEE features, including a new acoustic design with higher frequencies and bandwidth to provide increased resolution and tissue filling. Fast, easy and confident transthoracic and transesophageal echo allows clinicians to diagnose surgical pathology in real time.
  • HeartModel AI – The company’s Anatomical Intelligence Ultrasound (AIUS) application brings advanced automated quantification, 3-D views, robust reproducibility and significant time-savings to echocardiography quantification.
  • IntelliSpace Cardiovascular – Provides access to advanced cardiovascular informatics applications, brings multimodality images and clinical tools together in a single workspace for integrated clinical decision support. It seamlessly integrates with the IntelliSpace Portal advanced visualization solution, IntelliSpace ECG (electrocardiogram) data management solution, and the Philips Xper Information Management cath lab workflow solution.
  • DreamStation BiPAP autoSV Advanced – Designed to deliver optimal ventilation with minimal intervention for patients with central sleep apnea, complex sleep apnea and periodic breathing. Philips' clinically proven algorithm provides support when needed to help reduce events and normalize ventilation, and works with the patient's breathing pattern to minimize applied pressure, pressure support and machine breaths which can help patients experience comfortable, restful sleep.

Philips also highlighted new iFR (instant wave-Free Ratio) outcome results from over 4,500 patients. The data, which represent the largest randomized coronary physiology outcome studies to date, has the potential to help shape revascularization guidelines.

Read the article “Easier to Use iFR Equal to Outcomes of FFR in Coronary Lesion Evaluation.”

In addition to presenting data around the benefits of iFR technology, Philips hosted "Cardiology Talks," a program of short talks and conversation on key findings, trends and ideas impacting the cardiology specialty today. During the 20-minute sessions, clinicians, scientists and thought leaders shared their experiences and perspectives, discussed innovations, and invited attendees to join in the conversation.

For more information:

Related Content

Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors


News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the m
Overlay Init